There are troubling new signs that the overhaul of Medicare drug coverage in the Inflation Reduction Act is dramatically driving up program spending.
Why it matters: The upward trajectory could threaten some seniors' coverage for outpatient prescription drugs — and it could force painful tradeoffs over the next decade as Medicare consumes a growing share of the nation's debt.
Follow the money: The IRA limited what seniors have to pay for outpatient drugs and shifted the remaining cost to taxpayers, insurers who provide stand-alone Medicare drug plans and drug manufacturers.
That was good news for enrollees who take expensive drugs for conditions like cancer, multiple sclerosis or rheumatoid arthritis and faced potentially crushing out-of-pocket costs.
But federal data shows demand for drugs is surging as they become more affordable, exceeding congressional scorekeepers' spending estimates and setting off more alarms.
Driving the news: Last week, congressional Medicare advisers reported that more than 1 in 5 enrollees hit Medicare Part D's $2,000 patient cost cap in 2025 — shifting new costs to the government.
66% of total program drug spending was in this so-called catastrophic phase, when enrollees pay nothing for covered drugs and taxpayers and private Medicare plans pick up the cost.
Seniors' use of GLP-1 weight-loss drugs factored in the rise, with beneficiaries hitting the cost cap for these drugs earlier in the year than they did in 2024. Program spending surged from just $300 million in 2024 to $2 billion last year.
But there was double-digit spending growth across multiple classes of drugs, with cancer and diabetes treatments accounting for the largest spending increases.
Policy experts say the findings are important because Medicare drug plans have limited ability to control spending once enrollees hit the patient cost cap and face no cost sharing.
"The IRA gave plans an incentive to control spending, but few tools to do so," said American Enterprise Institute senior fellow Benedic Ippolito. "There are ways to modify the program that retain strong financial protections for enrollees while allowing for more cost containment."
Some analysts contend that overall Medicare spending will grow faster than the economy expands. The Cato Institute points to Congressional Budget Office projections showing Medicare drugs, doctors' visits and outpatient services will account for 44% of the federal deficit over the next decade.
But shifting more costs back onto seniors or cutting benefits could exacerbate health affordability concerns that already are leading some to skip medications and are driving up medical debt.
Between the lines: Predicting Medicare drug spending has always been tricky because it involves factoring an aging population, shifting costs and demand from seniors, and new laws like the IRA.
The increased use of specialty drugs has made drug expenses rise faster than other categories of medical spending.
Some of that has been offset by the use of lower-cost generics. And Medicare drug price negotiations starting this year are lowering the cost of some of the priciest brand-name medicines at the point of sale.
But Medicare trustees still project Part D drug costs will total about $222 billion this year, compared with $181 billion in 2025. By 2035, they're estimated to reach $346 billion.
What's next: The expiration of some provisions will likely shift more costs back on seniors.
A Biden-era program to stabilize insurance premiums will expire at the end of this year, meaning beneficiaries who buy stand-alone Medicare drug plans will pay more in January. The controversial program offers federal subsidies to insurers to keep patient monthly costs lower.
Further down the road, a 6% cap on annual increases in the Part D base premium expires in 2030. Subsidies now effectively absorb any difference.
Ippolito said Congress will have to reconsider the way the Medicare drug program is designed to control future spending, adding that extending current subsidy levels could easily cost over $100 billion for 10 years.
Options foranother drug coverage overhaul include charging enrollees copays for certain higher-priced drugs after they exceed the cap — or changing how the patient cap is calculated.
Ippolito said Congress also could allow Medicare drug plans to slowly raise premiums to more historically normal levels so taxpayers and seniors share program costs more evenly.
The bottom line: Even those kinds of changes may not solve the cost problem, meaning policymakers will need to consider basic questions like how much to spend on Medicare drugs.
Facts Only
* The Inflation Reduction Act limited what seniors must pay for outpatient drugs and shifted remaining costs to taxpayers, insurers, and drug manufacturers.
* Demand for drugs is surging as they become more affordable, exceeding congressional scorekeepers' spending estimates.
* More than 1 in 5 Medicare Part D enrollees hit the $2,000 patient cost cap in 2025, shifting costs to the government.
* 66% of total program drug spending was in a phase where enrollees paid nothing for covered drugs.
* Program spending surged from $300 million in 2024 to $2 billion in the preceding year.
* Spending growth included double-digit increases across multiple drug classes, with cancer and diabetes treatments being the largest increases.
* Medicare trustees project Part D drug costs will total about $222 billion this year, compared with $181 billion in 2025, estimated to reach $346 billion by 2035.
* The expiration of a program to stabilize insurance premiums will result in beneficiaries paying more for stand-alone Medicare drug plans starting in January.
* A 6% cap on annual increases in the Part D base premium expires in 2030.
Executive Summary
The Inflation Reduction Act has driven up Medicare spending on outpatient prescription drugs, shifting costs from enrollees to taxpayers, insurers, and drug manufacturers. This shift is significant because demand for drugs is surging as they become more affordable, exceeding prior spending estimates. Specifically, over 66% of total program drug spending occurred during the period when enrollees paid nothing for covered drugs. Costs have surged, with spending rising from $300 million in 2024 to $2 billion in the preceding year, driven largely by increased use of treatments for cancer and diabetes.
Policy experts note that Medicare drug plans have limited ability to control costs once enrollees reach the patient cost cap without cost-sharing. This situation is complicated by impending changes: a federal program stabilizing insurance premiums will expire, causing beneficiaries of stand-alone Medicare drug plans to face higher costs in January. Furthermore, caps on annual premium increases expire in 2030, and potential reforms being discussed include allowing plans to raise premiums or introducing copays for drugs exceeding the cap.
Full Take
The narrative centers on the tension between cost containment incentives created by legislation like the IRA and the reality of surging demand and growing expenditure. The mechanism described suggests that regulatory frameworks designed to control spending operate with limited levers once patient cost caps are reached, creating a structural impasse where increased utilization exacerbates financial strain for beneficiaries without offering immediate policy recourse beyond future legislative action.
The pattern observed is a cyclical shift: initial cost-sharing limitations lead to increased usage (demand surge), which then generates greater overall expenditure that outpaces initial budgetary projections. This suggests a fundamental misalignment between current spending models and the actual trajectory of pharmaceutical consumption, particularly for specialty drugs. The implications point toward an environment where attempts at short-term stabilization are insufficient to manage long-term fiscal reality. The proposed policy options—introducing copays or allowing premium increases—are framed not as simple adjustments but as re-engineering the core financial protections embedded in Medicare drug plans.
The missing dimension in this reporting is a deep inquiry into the incentives for pharmaceutical innovation versus cost containment, and whether current federal structures adequately balance these competing priorities for seniors. What assumptions about future economic growth versus government liability drive the projections regarding spending outpacing the economy? How can policy design be adjusted to decouple expenditure from sheer volume of utilization when market forces are already shifting costs onto payers?
Sentinel — Human
This piece reads like well-researched commentary synthesizing economic data and policy proposals, written from an analytical perspective rather than a purely informational one.